Vertex Pharmaceuticals

3 new FDA drug approvalsFDA recently approved 3 major drugs to treat lung cancer, prostate cancer, and cystic fibrosis. Here are the top 3 new drug approvals.
FDA expands cystic fibrosis treatmentFDA expanded the use of ivacaftor (Kalydeco, Vertex Pharmaceuticals) to treat cystic fibrosis.
Cystic fibrosis drug approved for younger patientsFDA recently expanded the use of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals) to treat cystic fibrosis in children aged 6 to 11 years who have two copies of the F508del mutation.
5 reasons to watch the new cystic fibrosis drugFDA’s approval last week of Vertex Pharmaceutical’s groundbreaking drug lumacaftor/ivacaftor (Orkambi) for cystic fibrosis is certainly good news, but formulary managers need to be aware of the high cost of the drug and other factors.
FDA drug approvals: March 2014FDA actions in brief, breakthrough therapy designations, priority review, fast-track designations, orphan drug designations
FDA approves simeprevir for hepatitis C virusFDA has simeprevir (Olysio, Janssen Therapeutics, Division of Janssen Products, LP) for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.
Vertex shifts focus to cystic fibrosis R&DVertex Pharmaceuticals is shifting its investment strategy to focus on opportunities in cystic fibrosis, according to CFO Ian Smith, who spoke at the Credit Suisse 2013 Healthcare Conference in mid November.